ResMed Inc (RMD)
Pretax margin
| Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,264,800 | 1,101,660 | 960,483 | 883,662 | 733,088 |
| Revenue | US$ in thousands | 4,685,300 | 4,222,990 | 3,578,130 | 3,196,820 | 2,957,010 |
| Pretax margin | 27.00% | 26.09% | 26.84% | 27.64% | 24.79% |
June 30, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $1,264,800K ÷ $4,685,300K
= 27.00%
The pretax margin of ResMed Inc has shown a relatively stable trend over the past five years, ranging from 24.79% in June 2020 to 27.06% in June 2021. In the most recent fiscal year ending June 30, 2024, the pretax margin improved to 27.02%. This indicates that the company has been effective in managing its operating expenses and generating operating income relative to its revenue. Overall, ResMed Inc has demonstrated consistent profitability before accounting for taxes over the analyzed period.
Peer comparison
Jun 30, 2024
Company name
Symbol
Pretax margin
ResMed Inc
RMD
27.00%
3M Company
MMM
20.25%
Artivion Inc
AORT
-1.93%
Baxter International Inc
BAX
-2.99%
Becton Dickinson and Company
BDX
9.94%
Boston Scientific Corp
BSX
13.63%
DexCom Inc
DXCM
17.58%
Embecta Corp
EMBC
3.95%
Glaukos Corp
GKOS
-38.49%
Globus Medical
GMED
4.79%
Haemonetics Corporation
HAE
15.58%